CARMAT is a medical device company developing the world's most advanced total artificial heart.
CARMAT aims to eventually provide a response to a major public health issue associated with heart disease, the world’s leading cause of death: chronic and acute heart failure.
CARMAT was founded in 2008 by Alain Carpentier. The company is headquartered in Paris, France.
CARMAT manufactures and markets the Aeson®, the world’s first physiological artificial heart that is highly hemocompatible, pulsatile and self-regulated. Aeson® could save, every year, the lives of thousands of patients waiting for a heart transplant.
Aeson® offers patients quality of life and mobility thanks to its ergonomic and portable external power supply system that is continuously connected to the implanted prosthesis. Aeson® is commercially available as a bridge to transplant in the European Union and other countries that recognize CE marking.
Aeson® is also currently being assessed within the framework of an Early Feasibility Study (EFS) in the United States.
Carmat is backed by European Investment Bank, Truffle Capital, and others. The company closed €40.5M in a Post-IPO Equity financing on Apr 12, 2022. This brings the total capital raised by Carmat to $214.2M to date.